InVivo Therapeutics Holdings had its investigational device exemption human trial approved by the FDA for a treatment of spinal cord injuries and neurotrauma conditions.

Amer Khalil, MD, of InVivo Therapeutics Holding in Cambridge, Mass., won an MDH Research Award to further InVivo's work on spinal cord injuries, according to Business Wire.

Former Stryker Spine executive Robert Housler Jr., has joined InVivo Therapeutics as vice president of business development.

Former Stryker biomaterials product development specialist Brian Hess was recently named director of product development at InVivo Therapeutics, according to an InVivo news release.

InVivo Therapeutics reported net income of $3 million for the third quarter of 2011, according to a company news release.

Spine device company InVivo Therapeutics has named Edward Wirth, MD, PhD, as the company's new chief science officer, according to an InVivo news release.

InVivo Therapeutics, based in Cambridge, Mass., was founded to focus on research and development of treatment for patients with spinal cord injuries (SCI). Currently, there are no effective treatments for these patients, and much of the research focuses on treating the symptoms of SCI instead of the underlying pathology.

However, InVivo has focused its efforts on both regenerative medicine and neuroprotection. Its scaffolds are designed to mitigate inflammation and prevent further cell death after SCI as well as support the repair and neuroplasticity recovery process. Co-founded by CEO and CFO Frank Reynolds and Robert Langer, ScD in 2005, InVivo Therapeutics and its scientific team have made incredible progress over the past few years and are now poised to bring the technology to human patients, which has created a stir in the global medical community.

InVivo Therapeutics, Cambridge, Mass.-based spine device company, reported a net loss of $1.3 million during the second quarter of 2011, according to a company news release.